Syndax Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

SNDX Syndax Pharmaceuticals Inc

CHEA Chenghe Acquisition Co

CRIS Curis Inc

PIXY ShiftPixy Inc

RVLP RVL Pharmaceuticals PLC

NAUT Nautilus Biotechnology Inc

BOF BranchOut Food Inc

SPRC Scisparc Ltd

NRSN Neurosense Therapeutics Ltd

ACNT Ascent Industries Co

Go

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 (revumenib) and SNDX-6352 (axatilimab). It is focused on developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged (MLLr), acute leukemias including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and nucleophosmin 1 (NPM1) mutant AML. Its axatilimab, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis (IPF). Its products candidate also includes entinostat, an oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells.